Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | The azacitidine plus romidepsin clinical trial in lymphoid malignancies

Owen O'Connor • 4 Dec 2015
ASH 2015
B-Cell Lymphoma T-Cell Lymphoma Azacitidine Romidepsin

Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about the Phase I trial (NCT01998035) looking into combining oral 5-azacitidine and romidepsin in patients with B-cell and T-cell lymphoma.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

More from Owen O'Connor

6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

1:13
Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta • 5 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals